Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a pivotal development as the FDA lifted the clinical hold on its investigational drug application for OCU200.
FDA Greenlights Ocugen’s Revolutionary Eye Treatment: What It Means for Vision Care Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will be participating in the 2024 Cell & Gene Meeting on the Mesa, scheduled for October 7-9 at the Arizona Biltmore in Phoenix, AZ. …
Ocugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the Mesa Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to participate in Chardan’s 8th Annual Genetic Medicines Conference in New York City.
Ocugen, Inc. to Feature at Chardan’s Genetic Medicines Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the 5th Annual Gene Therapy for Ophthalmic Disorders …
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will …
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced its financial results for the second quarter of 2024 and provided a business update.
Ocugen Reports Q2 2024 Financial Results and Business Update Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from the Food and Drug Administration to begin its expanded access program (EAP) for the treatment of adult patients with …
Ocugen Receives FDA Approval for Expanded Access Program for Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced the successful closing of its public offering of 30,434,783 shares of common stock on Friday. Each share was sold at $1.15, generating …
Ocugen Closes $35 Million Public Offering on Friday Read More